Tobacco smoking and severity of COVID-19: Experience from a hospital-based prospective cohort study in Lyon, France

Mitra Saadatian-Elahi1,2 | Sélimah Amour1,2 | Christelle Elias1,2 | Laetitia Henaff1,2 | Cédric Dananché1,2 | Philippe Vanhems1,2

Service Hygiène, Épidémiologie, Infectiovigilance et Prévention, Centre Hospitalier Édouard Herriot, Hospices Civils de Lyon, Lyon, France
2Public Health, Epidemiology and Evolutionary Ecology of Infectious Diseases (PHE3ID), Inserm - U1111, Lyon, France

Correspondence
Mitra Saadatian-Elahi, Service Hygiène, Épidémiologie, Infectiovigilance et Prévention, Centre Hospitalier Édouard Herriot, Hospices Civils de Lyon, Bâtiment 1, 5, place d’Arsonval-69437, Lyon cédex 3, Lyon, France.
Email: mitra.elahi@chu-lyon.fr

Funding information
Fondation AnBer; REACTing INSERM-FRANCE

Abstract
Information gathered so far from published studies attest the existence of a complex relationship between tobacco smoking and the severity of COVID-19. We investigated the association between smoking habits and the severity of COVID-19 in patients hospitalized in university-affiliated hospitals in Lyon, France. Baseline sociodemographic, clinical and biological characteristics of adult COVID-19 hospitalized patients presenting from the community were prospectively collected and analyzed. Tobacco exposure was documented at admission. Characteristics of patients hospitalized in medical wards to those admitted or transferred to intensive care units (ICUs) were compared using Mann–Whitney and Χ2 or Fisher’s exact test. A composite endpoint including admission or transfer to ICU or death was created as a proxy for severe outcome. Adjusted odds ratio (aOR) and 95% confidence interval (95% CI) were calculated to identify variables independently associated with a severe outcome. Of the 645 patients with documented information on smoking habits, 62.6% were never-smokers, 32.1% ex-smokers, and 5.3% active smokers. Past tobacco use was independently associated with an increased risk of severe outcome (aOR: 1.71; 95% CI: 1.12–2.63), whereas a nonsignificant protective trend was found for active smoking. The results suggest that past smoking is associated with enhanced risk of progressing toward severe COVID-19 disease in hospitalized patients.

KEYWORDS
COVID-19, France, hospital-based prospective study, SARS-CoV-2, smoking

1 | INTRODUCTION

Tobacco smoking, an established risk factor for a number of diseases including cardiovascular and chronic lung diseases, is also known to increase the susceptibility to viral respiratory infections.1 It would be, therefore, expected for smokers to be at increased risk of more severe clinical presentation by the ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The literature showed that the odds of being diagnosed with or hospitalized for COVID-19, the SARS-CoV-2 disease, are lower in smokers compared to never-smokers.2–4 Nevertheless, the evidence of the effect of tobacco consumption on the severity of COVID-19 remains equivocal.5,6

The concept of smoker’s paradox was first originated from observational studies that reported lower prevalence of smokers among hospitalized COVID-19 patients as compared to the national prevalence.7,8 Studies published so far reported paradoxical results; some studies have suggested that smoking would worsen the COVID-19 prognosis,9 whereas others reported absence of association10 or even a protective effect.3
Except few studies that differentiated between active and former smokers, others combined these two groups. Such group stratification analysis remains, however, pertinent to enable to distinguish the long-term impact of tobacco after cessation. The objective of this study was to investigate the impact of smoking habits on the severity of clinical presentation at admission and prognosis of laboratory-confirmed COVID-19 during hospitalization.

2 MATERIALS AND METHODS

Patients included in the present study were symptomatic hospitalized COVID-19 patients enrolled in one of the four university-affiliated hospitals in Lyon, France, for whom information on tobacco consumption was documented. These patients are part of the NOSO-COR project (ClinicalTrials: NCT04290780), a prospective, observational, hospital-based international study. The study was approved by the clinical research and ethics committee of Ile de France V on March 8, 2020 (No. 20.02.27.69817 Cat 3). Baseline demographic characteristics, underlying comorbidities, clinical and biological features, and patient outcome data were collected prospectively using electronic medical records. Information on tobacco smoking was based on self-reporting data. At hospital admission, patients were asked about their smoking status by the medical staff. Of the 1150 patients included in the NOSO-COR project by the end of Mai 2020, only 645 had documented information on tobacco smoking and were therefore included in the analysis. Clinical outcomes were monitored up to hospital discharge or death.

2.1 Statistical analysis

We compared characteristics of patients at hospital admission according to the smoking status. Categorical variables were described as number (%) and compared by X² test. Continuous variables were described as median (interquartile range [IQR]) and compared by Mann-Whitney U test. Statistical tests were two-tailed with a level of statistical significance of less than 0.05. A composite endpoint including admission or transfer to intensive care unit (ICU) or death as a proxy for disease severity was generated (Yes/No) and the risk to reach this outcome was estimated according to tobacco consumption status. Univariate logistic regression allowed the identification of variables at higher risk of severe outcome. The most significant variables (p < 0.05) were retained in the final model. Adjusted odds ratio (aOR) and 95% confidence interval (95% CI) were calculated by taking the non-smokers as the reference group. Statistical analysis was performed using STATA 13® (College Station).

3 RESULTS

The clinical features at admission of the enrolled patients are reported in Table 1. Of the 645 patients with documented information on smoking habits, 62.6% were never-smokers, 32.1% ex-smokers, and 5.3% active smokers. Date of smoking cessation was available for 30.4% of past smokers, with a length of abstinence ranging from 2 to 40 years. Ex-smokers were older than active or never-smokers. Cardiovascular disease and diabetes were the most common comorbidities in all three groups. Duration of symptoms and the delay between symptom onset and hospital admission were not different between the groups. The most commonly reported signs and symptoms were abnormal lung auscultation followed by dyspnea/tachypnoea and general weakness. Active smokers had significantly higher rate of chronic lung diseases as compared to never-smokers. Cardiovascular, renal and chronic lung diseases, shortness of breath, and dyspnea/tachypnoea have been found more frequently in ex-smokers compared to never-smokers. The most significant differences between active and ex-smokers were higher rates of cardiovascular disease and shortness of breath in ex-smokers. Hospitalization in ICUs and lethality were significantly higher in ex-smokers as compared to current or nonsmokers. A slight lymphocytopenia was observed among ex-smokers. The level of C-reactive protein (CRP) was higher than the reference range in all patients but was not different between the three groups. The median value of creatinine was significantly lower in ex-smokers as compared to never smokers although it remained within the reference range of 45–104 μmol/L.

The variables independently associated with a severe outcome are reported in Table 2. Ex-smokers were at significantly higher risk of severity (aOR: 1.71; 95% CI: 1.12–2.63) compared to nonsmokers, whereas nonsignificant trend toward decreased disease severity among current smokers as compared to never-smokers was observed (aOR: 0.54; 95% CI: 0.20–1.47). Patients with dyspnoea, longer duration of symptoms, temperature at admission, presence of underlying renal diseases, CRP > 100 mg/L, and monocytes < 0.3 g/L had higher odds of severe outcome.

4 DISCUSSION

The observed differences of outcomes between active and ex-smokers confirm the relevance of distinguishing these two populations when investigating the impact of smoking on the severity of COVID-19, considering the nonsmokers as the never-exposed population. Our results suggest that ex-smokers are at higher risk of ICU admission and death compared to active smokers. A meta-analysis of 18 published studies also reported that compared with ex-smokers, current smokers were less likely to experience an adverse outcome. In another meta-analysis, both current (relative risk [RR]: 1.25; 95% CI: 0.85–1.93) and former smokers (RR: 1.52; 95% CI: 1.13–2.07) were at higher risk of severe disease compared to never-smokers. However, this
| TABLE 1  Demographic and clinical characteristics at admission of confirmed COVID-19 hospitalized patients according to the smoking status (Lyon, France) | All patients (N = 645) | Current smoker (N = 34) (5.3%), G1 | Ex-smoker (N = 207) (32.1%), G2 | Never smoker (N = 404) (62.6%), G3 | p value (G1 vs. G3) | p value (G1 vs. G2) | p value (G2 vs. G3) |
|---|---|---|---|---|---|---|---|
| Age, median (IQR) | 71 (24) | 67.5 (26) | 72 (15) | 69 (28) | 0.272 | 0.014 | 0.008 |
| Age ≥ 75 years, n (%) | 253 (39.2) | 9 (26.5) | 87 (42.0) | 157 (38.9) | 0.153 | 0.086 | 0.449 |
| Age categories, n (%) | | | | | | | |
| <61 years | 175 (27.1) | 12 (35.3) | 33 (15.9) | 130 (32.2) | 0.054 | 0.010 | <0.001 |
| 61–80 years | 283 (43.9) | 18 (52.9) | 114 (55.1) | 151 (37.4) | | | |
| ≥81 years | 187 (29.0) | 4 (11.8) | 60 (29.0) | 123 (30.4) | | | |
| Gender, n (%) | | | | | | | |
| Female | 257 (40.1) | 10 (29.4) | 38 (18.4) | 209 (51.7) | 0.012 | 0.135 | <0.001 |
| Male | 388 (60.2) | 24 (70.6) | 169 (81.6) | 195 (48.3) | | | |
| Type of ward, n (%) | | | | | | | |
| Hospitalization in medical ward | 431 (66.8) | 27 (79.4) | 125 (60.4) | 279 (69.1) | 0.206 | 0.033 | 0.032 |
| Admission or transfer to ICU during hospitalization | 214 (33.2) | 7 (20.6) | 82 (39.6) | 125 (30.9) | | | |
| Comorbidities | | | | | | | |
| Cardiovascular disease | 336 (52.1) | 15 (44.1) | 130 (62.8) | 191 (47.3) | 0.723 | 0.039 | <0.001 |
| Diabetes | 160 (24.8) | 10 (29.4) | 62 (30.0) | 88 (21.8) | 0.305 | 0.949 | 0.026 |
| Chronic neurological diseases | 117 (18.1) | 9 (26.5) | 36 (17.4) | 72 (17.8) | 0.212 | 0.208 | 0.895 |
| Malignancy | 108 (16.7) | 3 (8.8) | 35 (16.9) | 70 (17.3) | 0.201 | 0.231 | 0.897 |
| Renal diseases | 100 (15.5) | 5 (14.7) | 45 (21.7) | 50 (12.4) | 0.694 | 0.349 | 0.003 |
| Chronic lung disease | 82 (12.7) | 9 (26.5) | 46 (22.2) | 27 (6.7) | 0.000 | 0.584 | <0.001 |
| Signs and symptoms at admission, n (%) | | | | | | | |
| Duration of symptoms (days), [n/N]a | [545/645]a | [26/34] | [171/207] | [348/404] | | | |
| Median (IQR) | 19 (14) | 18 (20) | 21 (15) | 18 (13) | 0.810 | 0.772 | 0.123 |
| Delays between onset of symptoms and hospital admission (days), [n/N]a | [626/645]a | [30/34] | [199/207] | [397/404] | | | |
| Median (IQR) | 6 (6) | 5 (5) | 6 (7) | 6 (6) | 0.514 | 0.523 | 0.881 |
| Temperature (°C), [n/N]a | [595/645] | [31/34] | [185/207] | [379/404] | | | |
| Median (IQR) | 38 (1.6) | 37.9 (1.3) | 38 (1.6) | 38 (1.5) | 0.088 | 0.247 | 0.258 |
TABLE 1  (Continued)

|                          | All patients (N = 645) | Current smoker (N = 34) | Ex-smoker (N = 207) | Never smoker (N = 404) | p value (G1 vs. G3) | p value (G1 vs. G2) | p value (G2 vs. G3) |
|--------------------------|------------------------|-------------------------|---------------------|------------------------|---------------------|---------------------|---------------------|
| Abnormal lung auscultation | 543/600 (90.5)         | 23 (85.2)               | 181/198 (91.4)      | 339/375 (90.4)         | 0.382               | 0.297               | 0.690               |
| Dyspnoea/tachypnea        | 466/600 (77.7)         | 19/27 (70.4)            | 165/198 (83.3)      | 282/375 (75.2)         | 0.576               | 0.102               | 0.025               |
| General weakness          | 457 (70.8)             | 21 (61.8)               | 142 (68.6)          | 294 (72.8)             | 0.170               | 0.430               | 0.280               |
| Cough                    | 451 (69.9)             | 19 (55.9)               | 140 (67.6)          | 292 (72.3)             | 0.043               | 0.180               | 0.233               |
| Shortness of breath       | 435 (67.4)             | 19 (55.9)               | 152 (73.4)          | 264 (65.4)             | 0.268               | 0.037               | 0.042               |
| Diarrhea                 | 182 (28.2)             | 11 (32.4)               | 48 (23.2)           | 123 (30.5)             | 0.817               | 0.249               | 0.059               |
| Myalgia                  | 122 (18.9)             | 7 (20.6)                | 25 (12.1)           | 90 (22.3)              | 0.820               | 0.175               | 0.002               |
| Nausea                   | 86 (13.3)              | 4 (11.8)                | 26 (12.6)           | 56 (13.9)              | 0.733               | 0.896               | 0.655               |
| Headache                 | 84 (13.0)              | 5 (14.7)                | 22 (10.6)           | 57 (14.1)              | 0.924               | 0.485               | 0.225               |
| Ageusia                  | 53 (8.2)               | 1 (2.9)                 | 15 (7.3)            | 37 (9.2)               | 0.216               | 0.350               | 0.423               |
| Anosmia                   | 45 (7.0)               | 1 (2.9)                 | 9 (4.4)             | 35 (8.7)               | 0.243               | 0.703               | 0.051               |
| Sore throat               | 28 (4.3)               | 1 (2.9)                 | 8 (3.9)             | 19 (4.7)               | 0.636               | 0.792               | 0.633               |

Laboratory measures admission

|                          | All patients (N = 645) | Current smoker (N = 34) | Ex-smoker (N = 207) | Never smoker (N = 404) | p value (G1 vs. G3) | p value (G1 vs. G2) | p value (G2 vs. G3) |
|--------------------------|------------------------|-------------------------|---------------------|------------------------|---------------------|---------------------|---------------------|
| Lymphocytes (g/L), median (IQR), Reference range: 1-4, [n/N]a | 0.97 (0.68), [603/645] | 1.08 (0.93), [33/34] | 0.88 (0.69), [194/207] | 0.98 (0.67), [376/404] | 0.154               | 0.027               | 0.077               |
| Monocyte (g/L), median (IQR), Reference range: 0.2-0.9, [n/N]a | 0.47 (0.36), [603/645] | 0.65 (0.47), [33/34] | 0.47 (0.34), [194/207] | 0.47 (0.36), [376/404] | 0.005               | 0.011               | 0.881               |
| CRP (mg/L), median (IQR), Reference range: <5, [n/N]a | 68.8 (106.8), [561/645] | 69 (89.6), [30/34] | 76.2 (98.5), [180/207] | 66.4 (111.8), [351/404] | 0.799               | 0.591               | 0.555               |
| Creatinine (μmol/L), median (IQR), Reference range: 45-104, [n/N]a | 83 (39), [601/645] | 84 (44), [32/34] | 90 (53), [195/207] | 80 (36), [374/404] | 0.185               | 0.493               | <0.001               |

Outcomea

|                          | All patients (N = 645) | Current smoker (N = 34) | Ex-smoker (N = 207) | Never smoker (N = 404) | p value (G1 vs. G3) | p value (G1 vs. G2) | p value (G2 vs. G3) |
|--------------------------|------------------------|-------------------------|---------------------|------------------------|---------------------|---------------------|---------------------|
| Death, n (%)             | 122 (18.9)             | 3 (8.8)                 | 61 (29.5)           | 58 (14.4)              | 0.371               | 0.012               | <0.001               |

Note: Categorical variables were described as number (%) and compared by Χ² test or Fisher’s exact test. Continuous variables were described as median (IQR) and compared by Mann-Whitney U test [n/N]. Abbreviations: CRP, C reactive protein; ICU, intensive care unit; IQR, interquartile range.

aNumber of available data compared to total patients and for each group.
Older age (> 65 years) is a recognized risk factor of SARS-CoV-2 infection in ex-smokers compared to active smokers. The higher prevalence of tobacco-related disease such as cardiovascular and renal diseases in ex-smokers might also further weaken this population. A misclassification bias of smokers as ex- or nonsmokers may have occurred as we investigated the smoking status from clinical records. Lack of information on the duration of smoking should be interpreted cautiously as it could counterbalance the trend against severe disease. The date of smoking cessation was available for one third of our study population. However, it is known that many smokers quit as soon as the occurrence of underlying diseases, which is parallel to aging. The relative advanced aged of our study population was much higher (24% overall and 10% in individuals >65 years old) than the recorded prevalence in our study population (5.3%).

As reported by others,7,8 smoking prevalence in the French population was much higher (24% overall and 10% in individuals >65 years old) than the recorded prevalence in our study population (5.3%).

The results of this study suggest differing effects of smoking on the severity of COVID-19 in hospitalized patients. Past smoking was associated with enhanced risk of progressing toward severe COVID-19 disease, whereas current smoking showed rather a nonsignificant protective trend against severe disease. The date of smoking cessation was available for one third of our study population. However, it is known that many smokers quit as soon as the occurrence of underlying diseases, which is parallel to aging. The relative advanced aged of our study population suggests that there is unlikely that they have stopped smoking just before developing COVID symptoms. High likelihood of misclassification bias, worse health-seeking behaviors, and self-treating in smokers15 and misreporting on the part of the patient by fear of stigmatization17 may explain, at least partly, the observed lack of an association between current smoking and adverse outcomes. Furthermore, the cross-sectional design of our study precludes definite information about cause-and-effect relationships.

There is a need for further evaluation of the complex relationship between smoking history and COVID-19 severity taking into account confounders such as age or obesity. Whether nicotinic agents such as nicotine patches could be used in the treatment of severe SARS-CoV-2 infection is being investigated in a double-blind randomized controlled clinical trial in France (NCT04608201).

The majority of cigarette smoke compounds have known oxidative stress properties and are therefore unlikely to have any potential protective. Consequently, any evidence of a potential protective impact of smoking should be interpreted cautiously as it could counterbalance the well-known deleterious effect of smoking on health.

**ACKNOWLEDGMENTS**

COVID-Outcomes-HCL Consortium: Laurent Argaud, Frédéric Aubrun, Marc Bonnefoy, Bruno Lina, Maude Boussambert-Duchamp, Roland Chapurlat, Dominique Chassard, Christian Chidiac, Michel Chuzeville, Cyrille Conclaves, Sébastien Couraud, Gilles Devouassoux, Isabelle Durieu, Michel Fessy, Sylvain Gaujard, Alexandre Gaymard, Arnaud Hot, Géraldine Martin Gaujard, Emmanuel Morelon, Vincent Piriou, Véronique Potinet, Jean-Christophe Richard, Thomas Rimmelle, Pascal Sève, Alain Sigal, Karim Tazarourte. Service Hygiène, Epidemiologie, Infectiovigilance et Prevention: Marie-Paule Gustin, Beatrice Grisi, Elodie Marion, Nagham Khanafer, Delphine Hilliquin, Sophie Gardes, Solveig Gembier-Colomban, Elisabetta Kuczewski. This study was supported by partial funding by

---

**Table 2** Multiple logistic regression analysis of variables independently associated with severe outcome in confirmed COVID-19 hospitalized patients according to the smoking status (Lyon, France)

| Smoking status       | Adjusted OR | 95% CI       | p value |
|----------------------|-------------|--------------|---------|
| Never smoker         | 1.0         | -            | -       |
| Ex-smoker            | 1.71        | 1.12-2.63    | 0.013   |
| Smoker               | 0.54        | 0.20-1.47    | 0.225   |

| Signs at admission   |             |              |         |
|----------------------|-------------|--------------|---------|
| Dyspnea              | 3.06        | 1.81-5.18    | <0.001  |
| Duration of symptoms | 1.04        | 1.03-1.06    | <0.001  |
| Temperature (°C)     | 1.25        | 1.01-1.53    | 0.038   |

| Comorbidities        |             |              |         |
|----------------------|-------------|--------------|---------|
| Renal diseases       | 2.67        | 1.55-4.60    | <0.001  |

| Laboratory parameters|             |              |         |
|----------------------|-------------|--------------|---------|
| CRP > 100 mg/L       | 2.05        | 1.36-3.09    | <0.001  |
| Monocytes < 0.3 g/L  | 3.09        | 1.88-5.07    | <0.001  |

Note: 1: reference group. Abbreviations: CRP, C reactive protein; 95% CI, 95% confidence interval; OR, odds ratio.
REACTing (Research and ACTion targeting emerging infectious diseases), INSERM, France, and a donation from Fondation AnBer (http://fondationanber.fr/). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

CONFLICT OF INTERESTS
As part of his research program and regardless of the present study, P. V. received grants and fees from Anios, Pfizer, Astellas, MSD, Gilead, and Sanofi. The remaining authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS
Conceptualization: Mitra Saadatian-Elahi and Philippe Vanhems. Data acquisition: Christelle Elias, Laetitia Henaff, and Cédric Dananché. Statistical analysis and validation: Mitra Saadatian-Elahi, Séllah Amour, and Philippe Vanhems. Writing-original draft: Mitra Saadatian-Elahi and Philippe Vanhems. Writing-review and editing: All

DATA AVAILABILITY STATEMENT
Data will be available upon reasonable request from the corresponding author (M. S. E.).

ORCID
Cédric Dananché http://orcid.org/0000-0002-0791-6391

REFERENCES
1. van Zyl-Smit RN, Richards G, Leone FT. Tobacco smoking and COVID-19 infection. Lancet Respir Med. 2020;8(7):664-665.
2. Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020;106(19):1503-1511. https://doi.org/10.1136/heartjnl-2020-317393
3. González-Rubio J, Navarro-López C, López-Nájera E, et al. A systematic review and meta-analysis of hospitalised current smokers and COVID-19. Int J Environ Res Public Health. 2020;17:7394.
4. Kowall B, Nonnemacher M, Brune B, et al. A model to identify individuals with a high probability of a SARS-CoV-2 infection. J Infect. 2021;82(3):e32-e34. https://doi.org/10.1016/j.jinf.2020.11.028
5. Farsalinos K, Bagos PG, Giannouchos T, Niaura R, Barbouni A, Poulas K. Smoking prevalence among hospitalized COVID-19 patients and its association with disease severity and mortality: an expanded re-analysis of a recent publication. Harm Reduct J. 2021;18(1):9. https://doi.org/10.1186/s12954-020-00437-5
6. Farsalinos K, Barbouni A, Poulas K, Polosa R, Caponnetto P, Niaura R. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2020;11:2040622320935765. https://doi.org/10.1177/2040622320935765
7. Farsalinos K, Barbouni A, Niaura R. Smoking review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Reply. Intern Emerg Med. 2020;16:1-2. https://doi.org/10.1007/s11739-020-02457-2
8. COVID-19 Response Team. CDC. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382-386. https://doi.org/10.15585/mmwr.mm6913e2
9. Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020;133(9):1032-1038. https://doi.org/10.1097/CM9.0000000000000775
10. Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med. 2020;75:107-108. https://doi.org/10.1016/j.ejim.2020.03.014
11. Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction. 2021;116(6):1319-1368. https://doi.org/10.1111/add.15276
12. Saadatian-Elahi M, Picot V, Henaff L, et al. Protocol for a prospective, observational, hospital-based multicentre study of nosocomial SARS-CoV-2 transmission: NOSO-COR Project. BMJ Open. 2020;10(10):e039088.
13. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-e25. https://doi.org/10.1016/j.jinf.2020.04.021
14. Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020;55(5):2000688. https://doi.org/10.1183/13993003.00688-2020
15. Farsalinos K, Niaura R, Le Houezec J, et al. Editorial: nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Rep. 2020;7:658-663. https://doi.org/10.1016/j.toxrep.2020.04.012
16. Berkowitz L, Schultz BM, Salazar GA, et al. Impact of cigarette smoking on the gastrointestinal tract inflammation: opposing effects in Crohn’s disease and ulcerative colitis. Front Immunol. 2018;9:74. https://doi.org/10.3389/fimmu.2018.00074
17. Alexandris N, Lagoumintzis G, Chasapis CT, et al. Nicotinic cholinergic system and COVID-19: in silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions. Toxicol Rep. 2020;8:73-83. https://doi.org/10.1016/j.toxrep.2020.12.013
18. Lagoumintzis G, Chasapis CT, Alexandris N, et al. Nicotinic cholinergic system and COVID-19: in silico identification of interactions between α7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-CoV-2 spike glycoproteins. Food Chem Toxicol. 2021;149:112009. https://doi.org/10.1016/j.fct.2021.112009
19. Ponti G, Maccaferrì M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389-399. https://doi.org/10.1080/10408363.2020.1770685
20. Reddy RK, Charles WN, Sklavounous A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID-19 severity: a systematic review and meta-analysis. J Med Virol. 2021;93(2):1045-1056. https://doi.org/10.1002/jmv.26389

How to cite this article: Saadatian-Elahi M, Amour S, Elias C, Henaff L, Dananché C, Vanhems P. Tobacco smoking and severity of COVID-19: Experience from a hospital-based prospective cohort study in Lyon, France. J Med Virol. 2021;93:6822-6827. https://doi.org/10.1002/jmv.27233